Bone Financial Statements From 2010 to 2026

BBLG Stock  USD 1.69  0.03  1.74%   
Bone Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bone Biologics' valuation are provided below:
Market Capitalization
3.1 M
Earnings Share
(2.40)
There are over one hundred nineteen available fundamental signals for Bone Biologics Corp, which can be analyzed over time and compared to other ratios. Active traders should verify all of Bone Biologics Corp prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. The Bone Biologics' current Enterprise Value is estimated to increase to about 8.1 M, while Market Cap is projected to decrease to roughly 3.4 M.
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 4.1 M, Ebitda of 101.3 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.3 or PTB Ratio of 2.32. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Build AI portfolio with Bone Stock
Check out the analysis of Bone Biologics Correlation against competitors.

Bone Biologics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding1.5 M1.4 M1.5 M
Slightly volatile
Other Current Liabilities5.1 K5.4 K740.5 K
Pretty Stable
Total Current Liabilities322.9 K339.9 K2.5 M
Very volatile
Other Stockholder Equity52.1 M101.8 M45.3 M
Slightly volatile
Total Liabilities322.9 K339.9 K4.7 M
Pretty Stable
Common Stock2.5 K2.7 K16 K
Pretty Stable
Short and Long Term Debt TotalM13.5 M8.7 M
Slightly volatile
Other Current Assets419.5 K616.7 K413 K
Slightly volatile
Accounts Payable221.8 K429 K196.9 K
Slightly volatile
Short and Long Term Debt7.2 M13.5 M8.7 M
Slightly volatile
Property Plant Equipment42.7545.03.8 K
Slightly volatile
Current Deferred Revenue602.3 K901.2 K488.2 K
Slightly volatile
Capital Stock2.5 K2.7 K19.6 K
Slightly volatile

Bone Biologics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses4.1 M4.9 M4.2 M
Pretty Stable
Depreciation And Amortization5.1 M4.9 M1.7 M
Slightly volatile
Selling General AdministrativeM1.9 M2.1 M
Pretty Stable
Research Development2.5 M2.4 MM
Pretty Stable
Interest Expense1.4 MM1.7 M
Very volatile
Tax Provision2.1 K3.7 K2.3 K
Slightly volatile
Selling And Marketing ExpensesM2.3 M2.5 M
Slightly volatile

Bone Biologics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.7 M3.5 M1.8 M
Slightly volatile
Total Cash From Financing ActivitiesM5.1 M3.2 M
Slightly volatile
End Period Cash FlowM3.8 M1.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield0.30.340.3689
Slightly volatile
Average Payables111.8 K117.7 K197.4 K
Slightly volatile
Capex To Depreciation0.120.1312.5824
Slightly volatile
Payables Turnover0.00130.00132.1577
Slightly volatile
Days Payables Outstanding233 K281.7 K225.1 K
Slightly volatile
Income Quality0.70.90.8354
Pretty Stable
Current Ratio6.49.210.0863
Slightly volatile
Capex Per Share0.00.08.4651
Slightly volatile
Interest Debt Per Share16.817.688.5 K
Slightly volatile
Debt To Assets347330180
Slightly volatile
Days Of Payables Outstanding233 K281.7 K225.1 K
Slightly volatile
Ebt Per Ebit1.551.121.4288
Slightly volatile
Quick Ratio6.49.210.0863
Slightly volatile
Net Income Per E B T0.750.90.8916
Slightly volatile
Cash Ratio6.167.929.781
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0161
Slightly volatile
Debt Ratio347330180
Slightly volatile

Bone Biologics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.4 M6.4 M4.4 M
Slightly volatile

Bone Fundamental Market Drivers

Bone Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bone Biologics Financial Statements

Bone Biologics stakeholders use historical fundamental indicators, such as Bone Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Bone Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bone Biologics' assets and liabilities are reflected in the revenues and expenses on Bone Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bone Biologics Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue901.2 K602.3 K

Currently Active Assets on Macroaxis

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:
Check out the analysis of Bone Biologics Correlation against competitors.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.40)
Return On Assets
(0.49)
Return On Equity
(0.80)
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.